Genomics and the future of pharmacotherapy in psychiatry

International Review of Psychiatry

Volumn 19, Issue 5, 2007, Pages 523-530

  Malhotra, Anil K ^a   Lencz, Todd ^b   Correll, Christoph U ^b   Kane, John M ^b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; HALOPERIDOL; MIRTAZAPINE; OLANZAPINE; PAROXETINE; RISPERIDONE; SEROTONIN 2A RECEPTOR;

CLINICAL TRIAL; DRUG RESPONSE; GENETIC ASSOCIATION; HEREDITY; HUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; PSYCHIATRY; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

GENOMICS; HUMANS; MENTAL DISORDERS; PHARMACOGENETICS; PSYCHIATRY; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS; WEIGHT GAIN;

EID: 34848907418     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.1080/09540260701563460     Document Type: Review

References (54)

1. Allison, D. B., Kaprio, J., Korkeila, M., Koskenvuo, M., Neale, M. C., & Hayakawa, K. (1996). The heritability of body mass index among an international sample of monozygotic twins reared apart. International Journal of Obesity Related Metabolic Disorders, 20, 501-506.
2. Angst, J. (1964). Antidepressiver effect und genetische faktoren. Arzneimittelforschung, 14( June suppl), 496-500.
3. Arinami, T., Gao, M., Hamaguchi, H., & Toru, M. (1997). A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Human Molecular Genetics, Apr, 6(4), 577-582.
4. Basile, V. S., Masellis, M, DeLuca, V., Meltzer, H. Y., & Kennedy, J. L. (2002). 759C/T genetic variation of 5HT2C receptor and clozapine-induced weight gain. The Lancet, 26, 128-129.
5. Caspi, A., Sugden, K., Moffitt, T. E., Taylor, A., Craig, I. W., Harrington, H., et al. (2003). Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science, 301(5631), 386-389.
6. Comuzzie, A. G., Blangero, J., Mahaney, M. C., Mitchell, B. D., Hixson, J. E., Samollow, P. B., et al. (1995). Major gene with sex-specific effects influences fat mass in Mexican Americans. Genetic Epidemiology, 12, 475-488.
7. Comuzzie, A. G., & Allison, D. B. (1998). The search for human obesity genes. Science, 280, 1374-1377.
8. Conley, R. R., & Kelly, D. L. (2001). Management of treatment resistance in schizophrenia. Biological Psychiatry, 50(11), 898-911.
9. Correll, C. U., & Malhotra, A. K. (2004). Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology, 174, 477-489.
10. de Leon, J., Armstrong, S. C., & Cozza, K. L. (2006). Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics, 47(1), 75-85.
11. Ellingrod, V. L., Perry, P. J., Ringold, J. C., Lund, B. J., Bever-Stille, K., Fleming, F., et al. (2005). Weight gain associated with the -759 C/T polymorphism of the 5HT2C receptor and olanzapine. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 134(1), 76-78.
12. Franchini, L., Serretti, A., Gasperini, M., & Smeraldi, E. (1998). Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. Journal of Psychiatry Research, 32, 255-259.
13. Green, M. F., Kern, R. S., Braff, D. L., & Mintz, J. (2000). Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the 'right stuff'? Schizophrenia Bulletin, 26(1), 119-136.
14. Horáček, J., Libiger, J., Höschl, C., Borzová, K., & Hendrychová, I. (2001). Clozapine-induced concordant agranulocytosis in monozygotic twins. International Journal of Psychiatry in Clinical Practice, 5, 71-73.
15. Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic. A doubleblind comparison with chlorpromazine. Archives of General Psychiatry, 45(9), 789-796.
16. Kane, J. M. (1996). Factors which can make patients difficult to treat. British Journal of Psychiatry Supplement, 13, 10-14.
17. Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J. Y., Sackler, R. S., Haynes, C., et al. (2005). Complement factor H polymorphism in age-related macular degeneration. Science, 308(5720), 385-389.
18. Lane, H. Y., Lee, C. C., Liu, Y. C., & Chang, W. H. (2005). Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics. Pharmacogenomics, 6(2), 139-149.
19. Lee, J. H., Reed, D. R., & Price, R. A. (1997). Familial risk ratios for extreme obesity: Implications for mapping human obesity genes. International Journal of Obesity Related Metabolic Disorders, 21, 935-940.
20. Lencz, T., Robinson, D. G., Xu, K., Ekholm, J., Sevy, S., Gundez-Bruce, H., et al. (2006). DRD2 Promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. American Journal of Psychiatry, 163(3), 529-531.
21. Leucht, S., Busch, R., Hamman, J., Kissling, W., & Kane, J. M. (2005). Rapid-onset hypothesis of antipsychotic drug action: A hypothesis tested, confirmed and extended. Biological Psychiatry, 57(12), 543-549.
22. Levine, J. A., Eberhardt, N. L., & Jensen, M. D. (1999). Role of nonexercise activity thermogenesis in resistance to fat gain in humans. Science, 283(5399), 212-214.
23. Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., et al., & Clinical Antipsychotic Trials on Intervention Effectiveness (CATIE) Investigators (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine, 353(12), 1209-1223.
24. Malhotra, A. K., Murphy Jr, G. M, & Kennedy, J. L. (2004). Pharmacogenetics of psychotropic drug response. American Journal of Psychiatry, 161(5), 780-796.
25. Malhotra, A. K., Athanasiou, M., Reed, C. R., Dain, B., Carr, J., Whalen, H., et al. (2005). Discovery of genetic markers associated with clozapine induced agranulocytosis. American Journal of Medical Genetics, Part B Neuropsychiatric Genetics, 138b(1), 22.
26. Mata, I., Madoz, V., Arranz, M. J., Sham, P., & Murray, R. M. (2001). Olanzapine: Concordant response in monozygotic twins with schizophrenia. British Journal of Psychiatry, 178(1), 86.
27. Mata, I., Crespo-Facorro, B., Perez-Iglesias, R., Carrasco-Marin, E., Arranz, M.J., Pelayo-Teran, J.M., et al. (2006). Association between the interleukin-1 receptor antagonist gene and negative symptom improvement during antipsychotic treatmentdagger. American Journal Medical Genetics Bulletin of Neuropsychiatric Genetics, in press.
28. McMahon, F. J., Buervenich, S., Charney, D., Lipsky, R., Rush, A. J., Wilson, A. F., et al. (2006). Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. American Journal of Human Genetics, 78(5), 804-814.
29. Miller, D. D., Ellingrod, V. L., Holman, T. L., Buckley, P. F., & Arndt, S. (2005). Clozapine-induced weight gain associated with the 5HT2C receptor-759C/T polymorphism. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 133(1), 97-100.
30. Montgomery, S. A. (1999). The failure of placebo-controlled studies. ECNP Consensus Meeting, September 13, 1997, Vienna. European College of Neuropsychopharmacology. European Neuropsychopharmacology, 9(3), 271-276.
31. Murphy Jr, G. M, Kremer, C., Rodrigues, H. E., & Schatzberg, A. F. (2003). Pharmacogenetics of antidepressant medication intolerance. American Journal of Psychiatry, 160(10), 1830-1835.
32. Pare, C. M.B., Rees, L., & Sainsbury, M. J. (1962). Differentiation of two genetically specific types of depression by the response to anti-depressants. The Lancet, 2, 1340-1343.
33. Pollock, B. G., Ferrell, R. E., Mulsant, B. H., Mazumdar, S., Miller, M., Sweet, R. A., et al. (2000). Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology, 23, 587-590.
34. Ratzoni, G., Gothelf, D., Brand-Gothelf, A., Reidman, J., Kikinzon, L., Gal, G., et al. (2002). Weight gain associated with olanzapine and risperidone in adolescent patients: A comparative prospective study. Journal of the American Academy of Child and Adolescent Psychiatry, 41(3), 337-343.
35. Reynolds, G. P., Zhang, Z. J., & Zhang, X. B. (2002). Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. The Lancet, 359, 2086-2087.
36. Reynolds, G. P., Zhang, Z. J., & Zhang, X. B. (2003). Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. American Journal of Psychiatry, 160, 677-679.
37. Reynolds, G. P., Yao, Z. J., Zhang, X. B., Sun, J., & Zhang, Z. J. (2005). Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. European Neuropsychopharmacology, 15(2), 143-151.
38. Reynolds, G. P., Arranz, B., Templeman, L. A., Fertuzinhos, S., & San, L. (2006). Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naïve psychotic patients. American Journal of Psychiatry, 163(10), 1826-1829.
39. Robinson, D. G., Woerner, M., Alvir, J., Ma, J., Bilder, R., Goldman, R., et al. (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry, 56, 241-247.
40. Robinson, D. G., Woerner, M. G., McMeniman, M., Mendelowitz, A., & Bilder, R. M. (2004). Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 161, 473-479.
41. Safer, D. J. (2004). A comparison of risperidone-induced weight gain across the age span. Journal of Clinical Psychopharmacology, 24, 429-436.
42. Sikich, L., Hamer, R. M., Bashford, R. A., Sheitman, B. B., & Lieberman, J. A. (2004). A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth; A double-blind, randomized, 8-week trial. Neuropsychopharmacology, 29(1), 133-145.
43. Smeraldi, E., Zanardi, R., Benedetti, F., DiBella, D., Perez, J., & Catalano, M. (1998). Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Molecular Psychiatry, 3, 508-511.
44. Tecott, L. H., Sun, L. M., Akana, S. F., Strack, A. M., Lowenstein, D. H., Dallman, M. F., et al. (1995). Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature, 374, 542-546.
45. Templeman, L. A., Reynolds, G. P., Arranz, B., & San, L. (2005). Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenetics and Genomics, 15(4), 195-200.
46. The International HapMap Consortium, (2005). A haplotype map of the human genome. Nature, 437, 1299-1320.
47. Theisen, F. M., Hinney, A., Bromel, T, Heinzel-Gutenbrunner, M., Martin, M., Kreig, J. C., et al. (2004). Lack of association between the -759C/T polymorphism of the 5-HT2c receptor gene and clozapine-induced weight gain among German schizophrenic individuals. Psychiatric Genetics, 14(3), 139-142.
48. Theisen, F. M., Gebhardt, S., Haberhausen, M., Heinzel-Gutenbrunner, M., Wehmeier, P. M., Krieg, J., et al. (2005). Clozapine-induced weight gain: A study in monozygotic twins and same-sex sib pairs. Psychiatric Genetics, 15, 285-289.
49. Tsai, S. J., Hong, C. J., Yu, Y. W., & Lin, C. H. (2002). -759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. The Lancet, 360, 1790.
50. Vojvoda, D., Grimmell, K., Sernyak, M., & Mazure, C. M. (1996). Monozygotic twins concordant for response to clozapine. The Lancet, 347, 61.
51. Wehmeier, P. M., Gebhardt, S., Schmidtke, J., Remschmidt, H., Hebebrand, J., & Theisen, F. M. (2005). Clozapine: Weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation. Psychiatry Research, 133, 273-276.
52. Wetterling, T., & Mussigbrodt, H. E. (1999). Weight gain: Side effect of atypical neuroleptics? Journal of Clinical Psychopharmacology, 19(4), 316-321.
53. Woods, S. W., Martin, A., Spector, S. G., & McGlashan, T. H. (2002). Effects of development on olanzapine-associated adverse events. Journal of the American Academy of Child and Adolescent Psychiatry, 41(12), 1439-1446.
54. Zanardi, R., Benedetti, F., DiBella, D., Catalano, M., & Smeraldi, E. (2000). Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. Journal of Clinical Psychopharmacology, 20, 105-107.